Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1Gastrointestinal 1

Conditions

Multiple Myeloma 28Neoplasms, Plasma Cell 9Neoplasms 7Lymphoma 6Leukemia 6Infections 5Hematologic Neoplasms 4Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Neoplasms by Site 2Neoplasms by Histologic Type 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Laryngeal Neoplasms 2Granuloma, Plasma Cell 2Glioma 2Erdheim-Chester Disease 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Sarcoma, Synovial 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Perivascular Epithelioid Cell Neoplasms 1Neurofibrosarcoma 1Nerve Sheath Neoplasms 1Nephrotic Syndrome 1Neoplasm Metastasis 1

Interventions

Pharmaceutical Preparations 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Familial Mediterranean Fever × Plasma cell × Clear all
NCT00035334 2006-02-14

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

Bellus Health Inc. - a GSK company

Phase 2/3 Completed
150 enrolled
GastrointestinalGenitourinaryPlasma cell

Amyloidosis, Arthritis, Rheumatoid, Gastrointestinal Diseases, Kidney Diseases, Neoplasm Metastasis, Nephrotic Syndrome, Familial Mediterranean Fever

Data powered by HemOnc (CC BY 4.0) Colophon âš¡